CX3CL1 expression is associated with poor outcome in breast cancer patients.

Breast cancer research and treatment

Volumn 140, Issue 3, 2013, Pages 495-504

  Tsang, Julia Y S ^a   Ni, Yun Bi ^b   Chan, Siu Ki ^b   Shao, Mu Min ^b   Kwok, Ying Kin ^b   Chan, Kit Wing ^b   Tan, Puay Hoon ^b   Tse, Gary M ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CX3CL1 PROTEIN, HUMAN; FRACTALKINE; TUMOR MARKER;

ADULT; AGED; BREAST TUMOR; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOKINE CX3CL1; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84898703407     PISSN: None     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2653-4     Document Type: Article

References (45)

1. Balkwill FR (2012) The chemokine system and cancer. J Pathol 226(2):148–157. doi:10.1002/path.3029
2. Corcione A, Ferretti E, Pistoia V (2012) CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. J Leukoc Biol 92(1):51–58. doi:10.1189/jlb.0112035
3. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of mem-brane-bound chemokine with a CX3C motif. Nature 385(6617): 640–644. doi:10.1038/385640a0
4. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188(8):1413–1419
5. Goda S, Imai T, Yoshie O, Yoneda O, Inoue H, Nagano Y, Okazaki T, Imai H, Bloom ET, Domae N, Umehara H (2000) CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and-independent mechanisms. J Immunol 164(8):4313–4320
6. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276(41):37993–38001. doi:10.1074/jbc.M106434200
7. Tsou CL, Haskell CA, Charo IF (2001) Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 276(48):44622–44626. doi:10.1074/jbc. M107327200
8. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91(4):521–530
9. Sciume G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G (2010) CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro Oncol 12(7):701–710. doi:10.1093/neuonc/nop076
10. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M (2005) The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26(1):41–47
11. Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R, Tanaka T (2008) Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8? T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 15(6):1775–1782. doi:10.1245/s10434-008-9876-3
12. Matsubara T, Ono T, Yamanoi A, Tachibana M, Nagasue N (2007) Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol 95(3):241–249. doi:10.1002/jso.20642
13. Guo J, Chen T, Wang B, Zhang M, An H, Guo Z, Yu Y, Qin Z, Cao X (2003) Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 89(1):1–7
14. Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, Ren H (2007) Gene therapy with CX3CL1/fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 14(16):1226–1234. doi:10.1038/sj.gt.3302959
15. Xin H, Kikuchi T, Andarini S, Ohkouchi S, Suzuki T, Nukiwa T, Huqun HK, Honjo T, Saijo Y (2005) Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 35(5):1371–1380. doi:10.1002/eji.200526042
16. Li F, Wang Z, Liu Y, Li J (2010) Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells. Oncol Rep 24(3):669–675
17. Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, Levi D, Rodriguez YBR, Gaetani P, Pelicci G, Allavena P (2010) Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer 46(18):3383–3392. doi:10.1016/j.ejca.2010.07.022
18. White GE, Greaves DR (2012) Fractalkine: a survivor’s guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol 32(3):589–594. doi:10.1161/ATVBAHA.111.237412
19. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A (2004) CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64(14):4693–4698. doi:10.1158/0008-5472.CAN-03-3437
20. Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadiere C, Prevot S, Machelon V, Balabanian K (2011) Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS ONE 6(7): e21546. doi:10.1371/journal.pone.0021546
21. Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Al-barello L, Doglioni C, Anselmo A, Doni A, Bianchi P, Laghi L, Malesci A, Cervo L, Malosio M, Reni M, Zerbi A, Di Carlo V, Mantovani A, Allavena P (2008) The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 68(21):9060–9069. doi:10.1158/0008-5472.CAN-08-1810
22. Xu X, Wang Y, Chen J, Ma H, Shao Z, Chen H, Jin G (2012) High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg 16(8):1493–1498. doi:10.1007/s11605-012-1921-7
23. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cris-tofanilli M (2006) Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17(6):945–951. doi:10.1093/annonc/mdl053
24. Jamieson-Gladney WL, Zhang Y, Fong AM, Meucci O, Fatatis A (2011) The chemokine receptor CX(3)CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Res 13(5):R91. doi:10.1186/bcr3016
25. Park MH, Lee JS, Yoon JH (2012) High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8? T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol 106(4):386–392. doi:10. 1002/jso.23095
26. Lacroix M, Toillon RA, Leclercq G (2004) Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11(3):497–522
27. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS (2006) Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8(2): R23. doi:10.1186/bcr1399
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235. doi:10.1007/s10549-006-9242-8
29. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histo-pathology 19(5):403–410
30. Lakhani SR, Ellis IO, Schnitee SJ, Tan PH, van de Vijver MJ (eds) (2012) World Health Organisation classification of tumors of the breast, 4th edn. IARC Press, Lyon
31. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/JCO. 2009.25.6529
32. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145. doi:10.1200/JCO. 2006.09.2775
33. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. doi:10.1093/jnci/djp082
34. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.1093/annonc/mdr304
35. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-0220
36. Huang YW, Su P, Liu GY, Crow MR, Chaukos D, Yan H, Robinson LA (2009) Constitutive endocytosis of the chemokine CX3CL1 prevents its degradation by cell surface metallopro-teases. J Biol Chem 284(43):29644–29653. doi:10.1074/jbc.M109. 045682
37. Morrison DH, Rahardja D, King E, Peng Y, Sarode VR (2012) Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer 107(2):382–387. doi:10.1038/bjc.2012.219
38. Vitale S, Cambien B, Karimdjee BF, Barthel R, Staccini P, Luci C, Breittmayer V, Anjuere F, Schmid-Alliana A, Schmid-An-tomarchi H (2007) Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 56(3):365–372. doi:10.1136/gut.2005.088989
39. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174–183. doi:10.1016/S1470-2045(09)70262-1
40. Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL (2006) AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116(1):261–270. doi:10.1172/JCI25888
41. Bhavsar PK, Sukkar MB, Khorasani N, Lee KY, Chung KF (2008) Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB. Faseb J 22(6):1807–1816. doi:10.1096/fj.07-094235
42. Adhikari AS, Singh BN, Rao KS, Rao ChM (2011) alphaB-crystallin, a small heat shock protein, modulates NF-kappaB activity in a phosphorylation-dependent manner and protects muscle myoblasts from TNF-alpha induced cytotoxicity. Biochim Biophys Acta 1813(8):1532–1542. doi:10.1016/j.bbamcr.2011. 04.009
43. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. doi:10.1016/j.stem.2007.08.014
44. Tsang JY, Huang YH, Luo MH, Ni YB, Chan SK, Lui PC, Yu AM, Tan PH, Tse GM (2012) Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Breast Cancer Res Treat 136(2):407–417. doi:10.1007/s10549-012-2271-6
45. Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, Schultz PG (2012) CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 107(1):43–52. doi:10.1038/bjc.2012.105